Race Oncology (ASX: RAC) – Hidden Gems Webinar. Presenter – Daniel Tillett – Chief Scientific Officer & Executive Director – Race Oncology is a precision oncology company with a Phase II/III cancer drug called Bisantrene. The drug is a potent small molecule inhibitor of the Fat mass and obesity associated (FTO) protein.
Subscribe to Our Newsletter
Get daily updates straight to your inbox.